Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
481-500 of 991 trials

Childhood Leukemia: Inotuzumab Ozogamicin vs. ALLR3

We are studying whether Inotuzumab Ozogamicin works better than standard treatment for children with high-risk first relapse B-cell leukemia. The trial focuses on safety and long-term effectiveness in young patients.

Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Multiple Myeloma: Mezigdomide vs. Pomalidomide

We are studying whether a new drug, mezigdomide, combined with bortezomib and dexamethasone, is more effective than pomalidomide with the same drugs for patients with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple Myeloma≤3 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Severe von Willebrand Disease: Vonicog Alfa Prophylaxis

We are studying whether vonicog alfa can help prevent bleeding episodes in children with severe von Willebrand disease. The trial will also look at the safety of this treatment over time.

Von Willebrand Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Stroke Treatment: Thrombolysis for Patients on Factor Xa Inhibitors

We are studying whether intravenous thrombolysis can improve recovery in stroke patients who have recently taken Factor Xa inhibitors. This trial compares the effects of this treatment to standard care options.

Acute Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Pegozafermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

We are studying whether pegozafermin can improve liver health in people with MASH and fibrosis compared to a placebo. This trial will help us understand its safety and effectiveness over time.

Nonalcoholic Fatty Liver Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology

Kidney Transplant: BIVV020 for Rejection Prevention and Treatment

We are studying BIVV020 to see if it can help prevent or treat antibody-mediated rejection in adults who have received a kidney transplant. This trial will assess its safety and how well it works compared to current treatments.

Transplant Rejection1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyInfectious DiseasesInternal MedicineOncology

Mucopolysaccharidosis IIIA: Gene Therapy Study

We are testing a new gene therapy called UX111 for individuals with Mucopolysaccharidosis IIIA. The goal is to see if it is safe and effective in treating this condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Bone Health: Alendronate Discontinuation Study

We are investigating the effects of stopping alendronate on fracture risk in patients with osteoporosis. The study also looks at whether specific health factors can predict bone loss after discontinuation.

Osteoporosis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOtolaryngology

ARDS Treatment: Recombinant Human Plasma Gelsolin

We are studying whether intravenous recombinant human plasma gelsolin is safe and may help patients with moderate-to-severe ARDS caused by pneumonia or infections. This trial compares it to a placebo alongside standard care.

Acute Respiratory Distress Syndrome (ARDS)≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPulmonology

Metastatic Squamous Non-Small Cell Lung Cancer: Pembrolizumab Study

We are studying the effects of pembrolizumab alone or with MK-2870 in patients with metastatic squamous non-small cell lung cancer. The goal is to see which treatment may improve survival and quality of life.

Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Lung Cancer: STX-241 Study

We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment

We are studying whether axatilimab, combined with corticosteroids, helps improve symptoms in patients with moderate to severe chronic graft-versus-host disease. This trial compares its effects to a placebo.

Chronic Graft-Versus-Host DiseaseConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Chronic Inflammatory Diseases: Low-Dose Interleukin-2 Therapy

We are studying the safety and effectiveness of low-dose interleukin-2 therapy for patients with conditions like Pemphigus vulgaris and Mucous Membrane Pemphigoid. This trial aims to see how well this treatment works compared to a placebo.

Primary Sclerosing Cholangitis (PSC)Mucous Membrane PemphigoidPolymyositis/Dermatomyositis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious DiseasesRheumatology

Head and Neck Cancer: Petosemtamab Treatment Study

We are studying the effects of petosemtamab in patients with advanced head and neck cancer who have not responded to previous treatments. The goal is to see if it improves survival and tumor response compared to standard therapies.

Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Hypereosinophilic Syndrome: Depemokimab Study

We are investigating whether Depemokimab can help adults with Hypereosinophilic Syndrome manage their symptoms better than a placebo. This study aims to provide insights into its effectiveness and safety.

Hypereosinophilic Syndrome1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Pneumococcal Vaccine Response: Age and HIV Impact

We are studying how age and HIV infection affect the immune response to pneumococcal vaccination. This research aims to improve vaccine effectiveness for different populations.

HIV Infection6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Severe Diffuse Cutaneous Systemic Sclerosis: Rapcabtagene Autoleucel vs. Rituximab

We are studying a new treatment to see if it works better than rituximab for people with severe diffuse cutaneous systemic sclerosis. The trial will also evaluate the safety of this new therapy.

Systemic Scleroderma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology